Poorly differentiated neuroendocrine carcinoma in a perigastric lymph node from an unknown primary site
- PMID: 23341792
- PMCID: PMC3546275
- DOI: 10.4143/crt.2012.44.4.271
Poorly differentiated neuroendocrine carcinoma in a perigastric lymph node from an unknown primary site
Abstract
Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.
Keywords: Lymph nodes; Neuroendocrine carcinoma; Unknown primary neoplasms.
Conflict of interest statement
Conflict of interest relevant to this article was not reported.
Figures



References
-
- Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly recognized clinicopathologic entity. Ann Intern Med. 1988;109:364–371. - PubMed
-
- Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol. 2009;36:52–59. - PubMed
-
- Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol. 2005;16:1374–1380. - PubMed
-
- Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548–3554. - PubMed
LinkOut - more resources
Full Text Sources